NasdaqGM - Delayed Quote • USD
Disc Medicine, Inc. (IRON)
At close: June 7 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 8 |
| Avg. Estimate | -1.17 | -1.24 | -4.96 | -5.41 |
| Low Estimate | -1.29 | -1.71 | -7.31 | -6.28 |
| High Estimate | -1.04 | -0.95 | -4.15 | -4.48 |
| Year Ago EPS | -0.74 | -0.58 | -3.42 | -4.96 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 8 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.86 | -0.8 | -0.78 | -1 |
| EPS Actual | -0.74 | -0.58 | -0.9 | -1.09 |
| Difference | 0.12 | 0.22 | -0.12 | -0.09 |
| Surprise % | 14.00% | 27.50% | -15.40% | -9.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.17 | -1.24 | -4.96 | -5.41 |
| 7 Days Ago | -1.17 | -1.24 | -4.96 | -5.41 |
| 30 Days Ago | -1.1 | -1.2 | -4.71 | -5.21 |
| 60 Days Ago | -1.04 | -1.08 | -4.67 | -5.26 |
| 90 Days Ago | -0.9 | -0.94 | -4.22 | -4.4 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | IRON | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -58.10% | -- | -- | 9.10% |
| Next Qtr. | -113.80% | -- | -- | 11.50% |
| Current Year | -45.00% | -- | -- | 5.70% |
| Next Year | -9.10% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/28/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Maintains | Raymond James: Outperform to Outperform | 5/10/2024 |
| Maintains | Stifel: Buy to Buy | 4/8/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/2/2024 |
Related Tickers
ELVN Enliven Therapeutics, Inc.
20.94
+3.66%
VRDN Viridian Therapeutics, Inc.
12.17
-0.49%
PHVS Pharvaris N.V.
15.67
-6.78%
KROS Keros Therapeutics, Inc.
48.69
0.00%
RGNX REGENXBIO Inc.
14.08
+2.33%
APGE Apogee Therapeutics, Inc.
41.69
-1.01%
CNTA Centessa Pharmaceuticals plc
8.80
-1.35%
PCVX Vaxcyte, Inc.
70.97
-2.12%
DNTH Dianthus Therapeutics, Inc.
20.13
-3.82%
IMTX Immatics N.V.
13.16
-2.45%